Kyverna Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Kyverna Therapeutics Inc KYTX.OQ reported a quarterly adjusted loss of 88 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-26.86. The mean expectation of five analysts for the quarter was for a loss of 84 cents per share. Wall Street expected results to range from -90 cents to -70 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Kyverna Therapeutics Inc's reported EPS for the quarter was a loss of 88 cents​.

• The company reported a quarterly loss of $37.49 million.

• Kyverna Therapeutics Inc shares had fallen by 33.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Kyverna Therapeutics Inc is $18.50

This summary was machine generated from LSEG data March 27 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)